Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A
International Journal of Molecular Sciences (2018)
Gene-expression analysis suggests GHK regulates dozens of pathways involved in tissue remodeling — a breadth unusual for a tripeptide and the basis for the renewed scientific interest in copper-peptide therapeutics beyond cosmetics.
This 2018 review by Loren Pickart — the discoverer of GHK and the longest-tenured researcher of the molecule — and Anna Margolina synthesizes the modern preclinical and clinical literature on GHK-Cu through the lens of recent gene-expression analyses. The authors argue that GHK's apparently broad effects (skin remodeling, lung repair, neuroprotection, anti-inflammatory action, anti-cancer activity, DNA repair support) reflect a genuine breadth of pathway modulation rather than a single tissue-specific mechanism. The review surveys evidence that GHK stimulates fibroblast collagen, elastin, and glycosaminoglycan synthesis; supports angiogenesis through copper-dependent mechanisms; modulates dozens of genes in dermal fibroblast and other cell-line analyses; and exhibits cytoprotective effects across skin, lung, bone, liver, and gastric tissues in animal models. The clinical-trial section summarizes the topical 12-week placebo-controlled studies in photoaged skin that anchor GHK-Cu's cosmetic adoption — including comparisons against vitamin C and retinoic acid creams in which GHK-Cu performed favorably for collagen-stimulation endpoints. The paper is the most current authoritative synthesis of GHK-Cu's mechanistic and clinical evidence in one place.
This is a narrative review, not a meta-analysis or systematic review — there is no risk-of-bias analysis or quantitative synthesis, and Pickart is the principal long-term advocate of the molecule. That isn't a disqualification (the field is small enough that the same investigator does much of the work), but the synthesis reflects one school's interpretation. Most of the evidence reviewed is preclinical: cell-line, animal-model, and small human cosmetic studies rather than large outcome-driven RCTs. The gene-expression findings are real but the translation from gene-level effect to clinical outcome is not established for most non-cosmetic indications. Readers seeking evidence for systemic injectable GHK-Cu use will find this review useful for mechanism but should not interpret it as evidence of clinical efficacy in non-skin contexts.